On Monday, Intra-Cellular Therapies reached an important technical benchmark, with its Relative Strength (RS) Rating climbing into the 90-plus percentile with an upgrade to 91, an increase from 82 the day before.
This exclusive rating from Investor's Business Daily tracks share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their biggest price moves.
How To Use Stock Charts To Stay Profitable And Protected
The IBD 50 stock is now considered extended and out of buy range after clearing a 93.45 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Intra-Cellular Therapies reported 0% EPS growth in the latest quarterly report. Sales gains came in at 39%.
The company earns the No. 25 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
